Effects of Mental Imagery With Self-regulation on Daily Activities in People With Parkinson's Disease
NCT07860294, Not applicable, Recruiting, The Hong Kong Polytechnic University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Mental Imagery With Self-regulation on Daily Activities in People With Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07860294 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The Hong Kong Polytechnic University | ClinicalTrials.gov |
| Conditions | Parkinson s Disease | ClinicalTrials.gov |
| Interventions | Mental imagery with self-regulation, Exercise and health education | ClinicalTrials.gov |
| First posted | 2026-10-06 | ClinicalTrials.gov |
| Last updated | 2026-10-06 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Canadian Occupational Performance Measure | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Canadian Occupational Performance Measure is a standardised client-centred outcome measure that assesses an individual's performance in daily activities (Law et al., 2005). This sensitive instrument focuses on participants' perceptions of their functioning and improvements in daily activities. | ClinicalTrials.gov |
| Secondary | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale assesses the non-motor and motor experiences of daily living and motor complications in People with Parkinson's Disease. | ClinicalTrials.gov |
| Secondary | Kinesthetic and Visual Imagery Questionnaire-10 | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Kinesthetic and Visual Imagery Questionnaire-10 will be used to assess motor imagery ability. It evaluates two dimensions of motor imagery: the clarity of visual imagery and the intensity of kinesthetic sensations associated with imagined movements. Participants first physically perform each movement and then imagine performing the same movement from a first-person perspective. | ClinicalTrials.gov |
| Secondary | Color Trails Test | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Color Trails Test assesses a person's executive functioning and is considered a sensitive test for detecting different types of brain damage in PwPD (D'Elia et al., 1989). CTT1 evaluates a person's visual scanning, sequencing, and processing speed; and CTT2 adds an alternating sequence component and is sensitive to executive functions such as mental flexibility and divided attention. | ClinicalTrials.gov |
| Secondary | Stroop Color and Word Test | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Stroop Color and Word Test assesses a person's mental flexibility - the ability to inhibit an automatic response and to establish and maintain a new, nonhabitual response based on environmental constraints. | ClinicalTrials.gov |
| Secondary | Timed Up and Go test | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The Timed Up and Go test is a standardised test that records the time taken by an individual to stand up from an armchair, walk 3 metres, turn and walk back at their usual speed, and sit on the chair again. | ClinicalTrials.gov |
| Secondary | 10-Meter Walk Test | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The 10-Meter Walk Test is recommended to measure gait speed in people with Parkinson's disease and is proven to be a reliable and valid measure. Gait speed is measured in metres per second over the middle 6 metres. | ClinicalTrials.gov |
| Secondary | European Quality of Life, Five Dimensions, Five Levels | Pre-intervention, at the end of the 6-week intervention, and at 3 and 6 months after intervention completion | The European Quality of Life, Five Dimensions, Five Levels instrument assesses five domains: mobility, self-care, usual activity, pain, and anxiety. Participants are asked to rate their self-perceived level of the five domains on a five-level scale of severity. | ClinicalTrials.gov |
| Other | Cortical Activity (mediator) | Pre-intervention and at the end of the 6-week intervention | Participants will complete a paper-and-pencil neuropsychological test and daily activity-related mental imagery tasks. During the 10-second baseline period, participants are required to sit on a chair until the task begins. During the 30-second task period, they will be instructed to complete the tests. The fNIRS recording session will be conducted in a quiet room. A 32-channel fNIRS optical topography system (NIRSport2; NIRx Medical Technologies, Berlin, Germany) will be utilised to monitor the oxygenation changes (i.e., oxy- to deoxy-hemoglobin proportion) in the cerebral cortices over the frontoparietal network (FPN), including the dorsolateral prefrontal cortex (DLPFC), ventrolateral prefrontal cortex (VLPFC), bilateral sensorimotor (SMC), bilateral premotor cortex (PMC), and bilateral supplementary motor area (SMA), throughout the Color Trails Test and daily activity-related mental imagery task paradigm. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)